

6-26-2019

## Drug interactions between direct-acting oral anticoagulants and calcineurin inhibitors during solid organ transplantation: considerations for therapy

Edwin Lam  
*Thomas Jefferson University*

Babar Bashir  
*Thomas Jefferson University*

Mark Chaballa  
*Thomas Jefferson University*

Walter K. Kraft  
Follow this and additional works at: <https://jdc.jefferson.edu/petfp>  
*Thomas Jefferson University*

 Part of the [Medical Pharmacology Commons](#)

[Let us know how access to this document benefits you](#)

---

### Recommended Citation

Lam, Edwin; Bashir, Babar; Chaballa, Mark; and Kraft, Walter K., "Drug interactions between direct-acting oral anticoagulants and calcineurin inhibitors during solid organ transplantation: considerations for therapy" (2019). *Department of Pharmacology and Experimental Therapeutics Faculty Papers*. Paper 108.  
<https://jdc.jefferson.edu/petfp/108>

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Pharmacology and Experimental Therapeutics Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: [JeffersonDigitalCommons@jefferson.edu](mailto:JeffersonDigitalCommons@jefferson.edu).

1 **Review Article Title:**  
2 Drug Interactions between Direct-Acting Oral Anticoagulants and Calcineurin Inhibitors during Solid  
3 Organ Transplantation: Considerations for Therapy  
4

5 **Authors & Affiliations:**

6 Edwin Lam, PharmD<sup>1</sup>, Babar Bashir, MD, MS<sup>2</sup>, Mark Chaballa, PharmD<sup>3</sup>, and Walter K. Kraft, MD<sup>1</sup>  
7

8 <sup>1</sup>Department of Pharmacology & Experimental Therapeutics, Thomas Jefferson University, Philadelphia,  
9 PA, USA

10 <sup>2</sup>Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA

11 <sup>3</sup>Department of Pharmacy, Thomas Jefferson University Hospital, Philadelphia, PA, USA  
12

13 **Corresponding author:**

14 Edwin Lam, PharmD; [edwin.lam@jefferson.edu](mailto:edwin.lam@jefferson.edu)

15 Department of Pharmacology & Experimental Therapeutics

16 Thomas Jefferson University

17 1170 Main Bldg; 132 S. 10th Street

18 Philadelphia, PA 19107-5244

19 Tel: (215) 955-5916

20 Fax: (215) 955-5681  
21

22 **Running Head (short title):**

23 DOAC and CNI PK/PD Interaction  
24

25 **Manuscript metrics:**

26 Title (with spaces)	150
27 Running title (with spaces)	30
28 Abstract (words)	190
29 Body of manuscript (words)	4983
30 References	77
31 Number of tables	1
32 Number of figures	2

33  
34  
35  
36  
37  
38  
39  
40  
41

42 **Abstract**

43 **Introduction:** There is a high incidence of venous thromboembolism (VTE) in solid organ transplant  
44 recipients. The safety and efficacy of direct-acting oral anticoagulants (DOAC) have been well established  
45 in clinical practice for the prevention and treatment of VTE in broad populations. However, the  
46 management of VTE in the setting of solid organ transplantation remains a challenge to clinicians due to  
47 limited evidence of DOAC usage with calcineurin inhibitors.

48

49 **Areas covered:** The current literature available on the pharmacokinetic-pharmacodynamic interaction  
50 between DOACs and calcineurin inhibitors is presented. A comprehensive review was undertaken using  
51 PubMed, Embase, drug product labeling, and drug product review conducted by the US Food and Drug  
52 Administration using Drugs@FDA. The potential for mitigation strategies and clinical management using  
53 extant knowledge is explored.

54

55 **Expert Opinion:** Immunosuppression therapy is necessary to prevent graft rejection by the host. The  
56 sparsity of data together with the lack of well-designed prospective studies of DOAC use in solid organ  
57 transplant recipients presents a unique challenge to clinicians in determining the clinical relevance of  
58 possible drug interactions. Existing evidence suggests that with attention to concomitant drug use and  
59 renal function, the co-administration of DOACs and calcineurin inhibitors is safe and effective.

60

61 **Keywords:** direct oral anticoagulants, DOAC, cyclosporine, tacrolimus, anticoagulation, venous  
62 thromboembolism, apixaban, rivaroxaban, dabigatran, warfarin

63 **Funding details:** Edwin Lam is supported by a National Institutes of Health training grant T32GM008562.

64 **Article Highlights**

- 65 • The calcineurin inhibitors, cyclosporine and tacrolimus, are commonly used in maintenance  
66 immunosuppression regimens to prevent graft rejection following solid organ transplant.  
67 Cyclosporine may have a higher likelihood of inhibiting drug metabolizing enzymes and transporters  
68 compared to tacrolimus.
- 69 • Direct oral anticoagulant (DOAC) clinical trials often excluded those on either cyclosporine or  
70 tacrolimus.
- 71 • Identifying intrinsic and extrinsic variabilities in the pharmacokinetics-pharmacodynamics in solid  
72 organ transplant recipients may balance the risks of bleeding while maintaining adequate  
73 anticoagulation.
- 74 • The Cockcroft-Gault formula using ideal body weight is used for dosing adjustments for apixaban and  
75 edoxaban while actual body weight is used to adjust dabigatran and rivaroxaban.
- 76 • While limited, pharmacokinetic-pharmacodynamic and outcomes evidence suggests safe and  
77 effective use of DOACs together with calcineurin inhibitors.
- 78 • Anti-Factor Xa monitoring is not standardized and is not helpful in dose selection.
- 79 • Direct oral anticoagulant use should be avoided in the immediate post-operative period and  
80 considered only after there is stability of renal and hepatic function and when bleeding risk has  
81 stabilized.
- 82 • Dose adjustment should not be made in the setting of acute thrombosis. After at least three months  
83 of therapy, intrinsic and extrinsic factors may inform the use of switching to attenuated dose for  
84 secondary thromboprophylaxis

85

86

87

88 **1. Introduction**

89 Solid organ transplantation offers a lifesaving option to patients with end-stage kidney, liver,  
90 heart, or lung disease. Between 1987 and 2012, 2 million life-years were saved by solid organ  
91 transplantation in the United States.[1] Acute and chronic immunosuppression therapy has been  
92 established as the cornerstone to prevent graft rejection, subsequent loss of the transplanted organ, and  
93 overall survival of the patient. Management of the transplant recipient using immunosuppression therapy  
94 is multi-modal where most immunosuppressive regimens include the calcineurin inhibitors (CNI)  
95 cyclosporine (CsA) and tacrolimus.[2-4]

96 Following solid organ transplantation, the incidence for venous thromboembolism (VTE) was 5%,  
97 14%, 29%, and 34%, for patients that underwent liver, renal, lung and heart transplant, respectively.[5]  
98 Although the reasons for higher incidence is not defined, factors including thrombophilic states (e.g.  
99 protein C, S or antithrombin III deficiency), clinical (e.g. diabetes mellitus, systemic lupus erythematosus),  
100 or donor-recipient (e.g. donor/recipient atheroma) have been proposed.[6] A thrombogenic state induced  
101 by immunosuppressive therapy has also been proposed based on in-vitro and clinical observations,  
102 however studies in renal transplant recipients remain contradictory.[7,8] Aside from the thrombogenic  
103 risk following organ transplant, risks for VTE are also inherent in patients who are greater than 40 years-  
104 old, immobile, or obese.[9]

105 The vitamin K antagonist warfarin has been the historical standard of care for the oral treatment  
106 of VTE. In solid organ transplant recipients, most protocols involve administering a parenteral  
107 anticoagulant (heparin or low molecular weight heparin) followed by warfarin maintenance for 3-6  
108 months.[5] In the general patient population, the direct acting oral anticoagulants (DOAC) are at least as  
109 efficacious as warfarin. They have fewer drug interactions, a wider therapeutic window, and a fixed-dose  
110 regimen without continuous monitoring of the coagulation profile. While these characteristics are

111 particularly appealing for use in clinical care, specific guidance in transplant patients is lacking since this  
112 population has been excluded from clinical trials of DOACs.

113           Calcineurin inhibitors block several drug transporters and metabolizing enzymes. Direct oral  
114 anticoagulants are substrates of specific drug transporters and metabolic enzymes involved in the  
115 absorption and elimination of drugs. Given the incidence of VTE following solid organ transplant and the  
116 prevalent use of CNIs in maintenance immunosuppressive regimens, the use of DOACs together with CNIs  
117 may result in a drug-drug interaction (DDI). These drug interactions are most impactful at treatment doses  
118 for labeled indications of venous thromboembolic disease or atrial fibrillation, rather than the lower doses  
119 used for primary prevention of venous thromboembolic disease.

120

## 121 **2. Maintenance Pharmacotherapy in the Solid Organ Transplant Recipients: Calcineurin Inhibitors**

### 122 **2.1. Tacrolimus**

123           Tacrolimus is a macrolide antibiotic isolated from *Streptomyces tsukubaensis*. Its mechanism  
124 involves complexation with the immunophilin FK-binding protein which produces immunosuppression by  
125 downstream inhibition of cytokine production and a loss of T-lymphocyte activation, proliferation, and  
126 response. Tacrolimus is part of maintenance immunosuppression in over 80% of kidney, pancreas, liver,  
127 intestine, heart, and lung transplant recipients and is indicated for the prophylaxis of organ rejection in  
128 kidney, liver and heart transplant.[10,11] Following oral administration, tacrolimus is extensively  
129 metabolized by cytochrome P450 (CYP) CYP3A4 and CYP3A5 and is a substrate for permeability  
130 glycoprotein (P-gp). It is unclear whether tacrolimus has the potential to inhibit drug metabolizing  
131 enzymes or efflux transporters in humans. While in-vitro and non-human in-vivo models have described  
132 a possible inhibitory effect on CYP3A4 and P-gp,[12] the pharmacokinetic impact of tacrolimus and other  
133 CYP3A and P-gp substrates in healthy volunteers is likely to be clinically irrelevant in patient  
134 populations.[13,14]

135

## 136 **2.2. Cyclosporine**

137 Isolated from the fungal species *Tolypocladium flatum* found in soil, cyclosporine was originally  
138 developed as an antifungal medication. Reduction in T-lymphocyte activity and immunosuppression by  
139 CsA occurs through the binding and complex formation with cyclophilin that results in downstream  
140 transcriptional inactivation of various interleukins and cytokines. Cyclosporine is extensively metabolized  
141 by CYP3A4 in the intestine and liver and is a P-gp substrate.[15] In addition, CsA is a potent inhibitor of  
142 intestinal and hepatic efflux transporters including breast cancer resistance protein (BCRP) and P-gp;  
143 hepatic uptake transporters such as organic anion transporting polypeptide (OATP); and CYP3A4. Drug  
144 metabolism by 3A4 takes place in liver and pre-systemically in the intestine. Due to its activity at the level  
145 of the intestines and liver, CsA may pose clinically relevant DDIs as both the victim and perpetrator drug.  
146 Cyclosporine is indicated for the prophylaxis of organ transplant rejection following kidney, liver, and  
147 heart transplantation.[16,17] Although tacrolimus appears to be the favored CNI in the US and Asia, there  
148 is still considerable global use of CsA.[18,19] Dose-dependent acute nephrotoxicity and chronic  
149 nephropathy from CsA exposure is a significant adverse event contributing to renal dysfunction following  
150 renal or non-renal transplant.

151

## 152 **3. Pharmacokinetics Following Transplantation: Absorption, Distribution, Metabolism, & Elimination**

153 A number of physiological changes occur after transplantation which impact drug disposition  
154 (**figure 1**). The major transplanted organs have a direct or indirect role in drug absorption, distribution  
155 and elimination. These changes are dynamic and can occur immediately following transplantation.  
156 Changes in gastric pH and emptying, gastrointestinal motility, incidence of diarrhea, bile dysfunction, and  
157 differential expression of drug efflux transporters following transplantation can alter absorption of drugs  
158 into the systemic circulation.[20-26] Drug distribution into tissues or free-fraction availabilities have also  
159 been shown to be impaired due to fluctuations in body weight or alterations in protein binding.[27-34]

160 Lastly, drug elimination may be altered due to higher hepatic blood flow, upregulation of drug  
161 metabolizing enzymes, changes in bile flow, or decline in renal function.[35-40]

162

#### 163 **4. Intrinsic and Extrinsic Factors Affecting DOAC Disposition in Solid Organ Transplant Recipients**

164 No formal studies have investigated the PK of DOAC therapy in solid organ transplant recipients.

165 Variability derived from intrinsic (altered protein binding, obesity, gastric motility) and extrinsic (DDI)

166 factors following transplantation may contribute to significant inter-recipient variability in the exposure

167 and the efficacy or safety response to DOACs. For the purposes of this review, extrinsic factors- mainly

168 those contributed from DDIs- will be discussed in detail. Drug metabolizing enzymes and transporters

169 play an important role in the disposition of drugs. The drug transporters, P-gp and BCRP, are commonly

170 expressed in the intestinal epithelia where their expression limits entry of therapeutic drugs.[41] In

171 excretory organs, drug transporters function to remove endogenous and xenobiotic compounds.

172 Therefore, efflux mechanisms can result in pharmacokinetic DDIs between CNI and DOACs during the

173 absorption or elimination phases. For CsA an interaction in the intestine can be considerable, since a large

174 magnitude of the delivered dose is in unbound form compared to delivery to the liver. In the intestines,

175 the inhibition of P-gp and BCRP by CsA was estimated using physiologically based pharmacokinetic

176 modeling to be up to 80% and 67%, respectively.[42] Moreover, up to 97% of intestinal CYP3A4 is inhibited

177 following a single oral dose. [42] In the intestines, P-gp, BCRP and CYP3A4 activity returns to maximal

178 activity within 4-6 hours after discontinuing CsA. Within the liver, P-gp, BCRP, and CYP3A4 enzyme activity

179 is estimated to be reduced by 4%, 2%, and 26%, respectively.[42] Tacrolimus has been shown to share

180 common inhibitory mechanisms as CsA with significantly less inhibition potential. For stabilized renal

181 transplant patients receiving tacrolimus, intestinal and hepatic CYP3A4 and P-gp activities are

182 insignificant. In contrast, the activity of intestinal CYP3A4 were starkly elevated in patients on CsA together

183 with significant reductions in intestinal and hepatic P-gp.[43] These findings enforce the differential

184 effects of CsA and tacrolimus on drug metabolizing enzymes and transporters for which a greater variation  
185 in drug exposure is anticipated for drugs co-administered with CsA. Clinically, the magnitude of tacrolimus  
186 inhibition on CYP3A4 and P-gp is expected to be minimal at therapeutic drug doses. [12,43]

187 It is important to keep in mind that although the magnitude of inhibition of transporters and  
188 enzyme may appear large, differential expression along the length of the small intestine and lower  
189 abundance of protein relative to the liver may minimize drug interaction potential.[44] In the case of the  
190 DOACs, clinically relevant DDIs may result at the level of absorption (i.e. the intestines) or elimination (i.e.  
191 renal or non-renal routes) when given together with CsA or tacrolimus. All DOACs are substrates of drug  
192 efflux transporters and, with the exception of dabigatran, substrates for CYP3A4. Use of P-gp or CYP3A4  
193 inhibitors, especially CsA or tacrolimus, were mostly excluded from pivotal trials in patients during the  
194 clinical development of each DOAC.[45-48] While information related to the clinical relevance of the DDI  
195 in patient populations is limited, available PK studies in healthy volunteers may provide insight in the  
196 magnitude of change and its relationship to safety and efficacy. **Table 1** summarizes the extrinsic factors  
197 relating to DDIs for DOACs and their respective exposure and peak concentration changes in the presence  
198 of their substrate transporter and/or enzyme inhibitor. In the absence of a dedicated CsA or tacrolimus  
199 study, we reference available substrate transporter and/or enzyme inhibitors that share the same  
200 mechanistic pathways to provide insight to the magnitude of changes in the exposure and peak  
201 concentrations.

#### 202 **4.1. Dabigatran**

203 Dabigatran etexilate directly and reversibly inhibits thrombin, rather than reducing the  
204 production of vitamin K dependent clotting factors.[49] Dabigatran etexilate is a prodrug that is orally  
205 absorbed with an absolute bioavailability of approximately 3-7%. Conversion to the active moiety,  
206 dabigatran, is independent of CYP isoenzymes and is formed following hydrolysis by carboxylesterases. It  
207 is the prodrug that is a substrate of P-gp rather than the active moiety, which may account for its low

208 bioavailability and variable PK. In addition, changes in gastric pH and intestinal motility have also  
209 contributed to the observed differences in PK following surgery.[50] The volume of distribution is  
210 moderate at 60 liters with an in-vitro plasma protein binding of 35% across therapeutic concentrations.  
211 Dabigatran, but not dabigatran etexilate, is detectable in systemic circulation following oral  
212 administration. Dabigatran metabolism is minimal and it is not a substrate or inhibitor of CYP450 enzymes.  
213 Renal clearance is the major route of dabigatran drug elimination representing 80% of the total clearance.  
214 Following intravenous dosing, greater than 80% of the dose was recovered in the urine compared to only  
215 7% after oral administration. The remaining 86% of orally dosed dabigatran was recovered in the feces  
216 most likely due to incomplete absorption of DE. Dabigatran elimination half-life is 12-17 hours.

217 Dabigatran etexilate exhibits predominately P-gp dependent transport, demonstrated by in-vitro  
218 inhibition studies using verapamil as a P-gp inhibitor.[51] In the presence of CsA, a P-gp and BCRP inhibitor,  
219 greater than 80% of efflux was inhibited as observed using the same in-vitro Caco-2 permeability model.  
220 These results implicate CsA as a potential perpetrator for clinical in-vivo drug interactions following co-  
221 administration with dabigatran etexilate. To date, no dedicated in-vivo clinical studies have been  
222 conducted evaluating the DDI between dabigatran etexilate co-administered with either CsA or  
223 tacrolimus. P-gp inhibition may be time-dependent and influenced by the timing of a co-administered  
224 perpetrator. Following multiple oral doses of verapamil in healthy volunteers, total dabigatran exposure  
225 and peak concentration increased by 54% and 63% after a single-oral 150 mg dabigatran etexilate dose 1  
226 hour after verapamil, respectively.[52] When dabigatran etexilate was given 2 hours prior to verapamil,  
227 exposure and peak concentration increased by 18% and 12%, respectively. Considering the inhibition  
228 activity of CsA in-vitro, results from co-administered verapamil alone may not satisfy the clinical relevance  
229 of both P-gp and BCRP inhibition. Insightful results based on in-silico modeling using ritonavir, a dual P-gp  
230 and BCRP inhibitor, have estimated exposure and peak concentration increases of approximately 25% and  
231 16%, using a simulated 200 mg twice-daily regimen, respectively.[53]

232 Dabigatran transporter mediated DDIs are best assessed using data obtained in healthy  
233 volunteers using the broad ATP-binding transporter and CYP3A4 inhibitor ritonavir.[54] Following  
234 multiple-oral doses of ritonavir 100 mg daily, single-dose dabigatran exposure was increased by 15% when  
235 administered simultaneously and reduced by 29% when dabigatran etexilate was administered 2 hours  
236 prior to dosing ritonavir. These observations likely confirm the time-dependency of co-administered  
237 perpetrator drugs on the PK profile of dabigatran. P-gp inhibition and renal dysfunction are both  
238 independent factors that enhances the exposure of DE.

239 In patients receiving dabigatran etexilate for treatment and prevention of VTE, there is no dosage  
240 adjustment or contraindication to P-gp inhibitors so long as patients have a creatinine clearance greater  
241 than 50 mL/min.[55] These recommendations are intuitive considering the most important factor  
242 influencing dabigatran exposure is renal clearance. Therefore, the use of dabigatran etexilate is  
243 completely contraindicated in those with creatinine clearances less than 50 mL/min. Despite these results,  
244 the U.S. labelling for CsA suggests avoiding co-administration with dabigatran etexilate altogether  
245 regardless of renal function.[16,17] Drug-drug interactions involving dabigatran etexilate may be  
246 restricted to only intestinal P-gp rather than other sites. In addition, BCRP and CYP3A4 liability is not a  
247 general concern as witnessed from in-vitro permeability models and clinical DDI studies using the P-gp,  
248 BCRP and CYP3A4 inhibitor, ritonavir. Based on these findings, dabigatran is a suitable choice in transplant  
249 patients co-prescribed CsA or tacrolimus, so long as estimated creatinine clearance is > 50 ml/min. As the  
250 risk of higher exposures and subsequent bleeding risk will be low in those with creatinine clearances  
251 greater than 50 mL/min using a CNI, caution should be enforced especially during periods of fluctuating  
252 physiology during the post-transplant period. A shorter acting parenteral anticoagulant should be  
253 considered before dabigatran until renal function stabilizes and the bleeding risk has declined. In the  
254 setting of acute VTE, the label outlines at least five days of treatment be with a parenteral agent (heparin  
255 or enoxaparin) before transitioning to dabigatran etexilate.

### 256 4.3. Rivaroxaban

257 Rivaroxaban is a direct oral factor Xa (FXa) inhibitor approved by the FDA for the treatment and  
258 prevention of recurrent VTE and reducing risk of stroke in atrial fibrillation.[56] Absolute bioavailability is  
259 dose dependent where almost complete absorption (80 to 100%) is achieved at the 10 mg dose but  
260 reduced to 66% for the 20 mg dose. The site of absorption is primarily in the proximal small intestine  
261 where peak concentrations are observed 2 to 4 hours following oral intake. Rivaroxaban is highly bound  
262 to plasma proteins with a steady-state volume of distribution of 50 liters. Approximately two-thirds of  
263 the administered dose is subjected to metabolic transformation through CYP3A4/5 and CYP2J2  
264 metabolism where it accounts for 18% and 14% of the total rivaroxaban elimination, respectively. No  
265 major active circulating metabolites in plasma are present following administration. The remaining one-  
266 third of the administered dose is eliminated renally as unchanged drug where 30% is removed through  
267 active renal secretion and the remaining 6% through glomerular filtration. The elimination half-life in  
268 healthy subjects is 5 to 9 hours whereas elderly subjects had prolonged half-lives ranging from 11 to 13  
269 hours. Rivaroxaban is a substrate for the efflux transporters P-gp and BCRP and has equal affinity for both  
270 transporters.[51]

271 Based on pooled phase I results, the impact of age, race, renal and hepatic insufficiency were  
272 observed to influence the area under the concentration-time curve (AUC). Healthy elderly subjects older  
273 than 75 years of age have greater than 40% higher exposures, primarily due to a decline in renal function  
274 and non-renal rivaroxaban clearance.[57]. A dose-reduction strategy is recommended to account for renal  
275 function based on creatinine clearance.[56]

276 Although there is no dedicated DDI study with CsA, similar perpetrator inhibitors- such as  
277 erythromycin- sharing the same inhibitory pathway may offer an insight in the magnitude of  
278 interaction.[58] Erythromycin is a combined P-gp and moderate CYP3A4 inhibitor which shares the same  
279 characteristic as CsA. Following multiple-doses of erythromycin, the AUC and peak concentrations are

280 increased by 34% and 38% after a single-dose of rivaroxaban. Similarly, the AUC and Cmax are increased  
281 by 42% and 28% following co-administration with the combined moderate CYP3A4 and BCRP inhibitor  
282 fluconazole. These individual elevations in the AUC and peak concentrations alone do not warrant a  
283 dosage change or contraindication as these values fall within the ranges observed of drug use in the  
284 general patient population. Although one intrinsic or extrinsic factor alone does not preclude the use of  
285 rivaroxaban, the presence of greater than one factor may present a complex drug-drug and drug-disease  
286 interaction producing a clinically significant increase in rivaroxaban exposure. When accounting for renal  
287 function, age, and DDI with erythromycin, increase in the AUC by 1.9, 2.4, and 2.6-fold were predicted in  
288 younger patients with mild, moderate, or severe renal impairment while co-administered erythromycin,  
289 respectively.[59] The impact from older age with erythromycin (55-65 years old) predicted a 2.5, 2.9 and  
290 3-fold increase in the AUC in individuals with mild, moderate or severe renal impairment, respectively.  
291 Although these results should not be extrapolated to those using CsA or tacrolimus, cautious monitoring  
292 and careful clinical consideration for rivaroxaban use should be practiced especially in older patients with  
293 reduced renal function.

#### 294 **4.4. Edoxaban**

295 Edoxaban is a selective inhibitor of FXa indicated for the risk reduction of stroke and emboli in  
296 non-valvular atrial fibrillation and treatment of VTE.[60] Like dabigatran but unlike the other FXa  
297 inhibitors, edoxaban is labeled to be started after 5 to 10 days of parenteral anticoagulation in the  
298 treatment of acute VTE. Edoxaban demonstrates pH-dependent solubility where optimal dissolution is  
299 achieved in the pH range of 3 to 5. Absorption primarily occurs in the proximal small intestine with an  
300 absolute bioavailability of 62%. The volume of distribution is estimated to be 107 liters and plasma protein  
301 binding is estimated to be about 55% for concentrations from 0.2 to 5 ug/mL. Edoxaban metabolism is  
302 primarily mediated by carboxylesterase 1 (CES1) and CYP3A4. M4, an active circulating metabolite in  
303 plasma, is formed following CES1 metabolism and contributes to 10% of the total edoxaban systemic AUC.

304 Approximately 50% of the total clearance of unchanged edoxaban is through the kidneys with the  
305 remaining half appearing in feces and bile. After oral administration, the terminal elimination half-life is  
306 10 to 14 hours. Edoxaban is a substrate for P-gp with its active metabolite, M4, a substrate for the influx  
307 transporter OATP1B1. In-vitro evidence suggests equivalent efflux transport from P-gp and BCRP.[51]

308 In the registration trial for use in VTE, study patients on concurrent P-gp inhibitors with body  
309 weight  $\leq$  60 kg or moderate renal impairment received an edoxaban dose reduction to 30 mg daily with  
310 patients on CsA excluded from the study.[47] Edoxaban prolongs the prothrombin time in a  
311 concentration-dependent manner with a linear relationship between edoxaban and anti-FXa. The AUC of  
312 drug concentration is a predictor of therapeutic response when compared to warfarin across subjects with  
313 normal, mild, or moderate renal function.[61]

314 The interaction between edoxaban and CsA has been evaluated in healthy volunteers. Co-  
315 administration with CsA resulted in a 73% increase in edoxaban peak concentration and 72% increase in  
316 AUC.[62] Furthermore, the active circulating metabolite was observed to increase by greater than 7-fold  
317 for the both peak concentrations and AUC. In the population pharmacokinetic analysis of all VTE studies,  
318 no significant exposure-response for bleeding was observed in patients on 30 mg daily, however the  
319 risk of recurrent VTE was modestly higher (1.77% vs. 1.57%) compared to patients on 60 mg.[63] The  
320 product label outlines 30 mg once daily dose of edoxaban for patients with creatinine clearances between  
321 15 to 50 mL/min, body weight  $\leq$  60 kg, or those on certain P-gp inhibitors.[60]

#### 322 **4.5. Apixaban**

323 Apixaban is indicated for the treatment and prevention of VTE and reducing the risk of stroke in  
324 atrial fibrillation.[64] Absorption occurs primarily in the upper gastrointestinal tract with a reduction in its  
325 absorption witnessed in more distal sites of the intestines.[65] Alterations in gastric acidity is not  
326 anticipated to produce significant changes since apixaban has no ionizable groups across physiological pH.  
327 Apixaban has an absolute bioavailability of approximately 50% and demonstrates dose-proportional

328 increases in AUC for oral doses up to 10 mg. Approximately 87% of drug is bound to protein while the  
329 distribution volume is low at 21 liters. Metabolism is predominately through CYP3A4 with a quarter of its  
330 metabolites appearing in urine and feces. Less than a third of apixaban is eliminated through renal  
331 excretion whereas the remaining fraction occurs through biliary and intestinal secretion into the feces.

332 Apixaban is a substrate for P-gp and BCRP with an estimated half-life of 12 hours. Using in-vitro  
333 permeability and transport assays with transfected cell monolayers, apixaban undergoes concentration  
334 and time-dependent transport via P-gp and BCRP with efflux ratios between 23-38 and 8-12,  
335 respectively.[66] In inhibition studies using Caco-2 bidirectional monolayers together with CsA, a non-  
336 specific inhibitor of P-gp and BCRP, the observed inhibition of apixaban efflux was 64%.[51] The efflux of  
337 apixaban is inhibited by 13% in comparison to verapamil, a strong and specific inhibitor of P-gp. As a result,  
338 although P-gp has a role in apixaban intestinal efflux, BCRP-dependent transport may predominate.

339 A concentration-dependent increase in anti-FXa activity is observed following single and multiple  
340 oral doses of apixaban. Intrinsic and extrinsic covariates that predicted apixaban total clearance are age,  
341 sex, race, renal function and co-administration of dual moderate and strong CYP3A4 and P-gp  
342 inhibitors.[67] Independent contributions from age, sex, race, and co-medications resulted in less than a  
343 25% increase in apixaban exposures. Those with mild, moderate and severe renal dysfunction were found  
344 to have 17%, 34%, and 56% higher exposures, respectively.

345 Considering that close to one-third of the total systemic clearance of apixaban is due to renal  
346 elimination, decline in renal function is expected to largely affect the magnitude of exposure. Although  
347 intrinsic covariates such as age, sex, and race identified less than a quarter change in apixaban exposures,  
348 clinicians should be cognizant of additive effects when multiple factors are present. Declining renal  
349 function from CNI exposure may also be synergistic with previously mentioned factors and can potentially  
350 contribute to higher apixaban exposures. The PK of apixaban was evaluated in 12 healthy male volunteers  
351 together with CsA and tacrolimus. Following multiple-doses of CsA and tacrolimus, the AUC and  $C_{max}$  of a

352 single 10 mg apixaban dose was observed to increase by 20% and 43% for CsA but decline by 22% and  
353 13% for tacrolimus when compared to apixaban alone, respectively.[68] The contrasting effects of  
354 cyclosporine and tacrolimus on apixaban exposure noted in the study were unexpected, and the  
355 mechanism unclear. Based on safety analyses, elevated apixaban exposure and peak concentrations alone  
356 after co-administration with CsA is not anticipated to pose any clinically relevant bleeding events. In the  
357 case of tacrolimus, a 22% reduction in exposure may not result in loss of efficacy as witnessed in subjects  
358 with body weights  $\geq 120$  kg. With a 25% decline in apixaban exposures due to extreme body weight, a  
359 third as many patients experienced a stroke or thromboembolic compared to warfarin observed from  
360 pivotal trials in atrial fibrillation.[69] Additionally, although within the lower bounds of apixaban  
361 exposures, tacrolimus co-administration is not expected to confer loss of efficacy at the indicated 2.5 mg  
362 twice-daily dose for VTE prophylaxis.[67] Although each factor is independent, the synergism from body  
363 weight being greater than 120 kg and tacrolimus use should warrant further clinical monitoring as the  
364 combination of both may compromise efficacy.

365

366 **8. Conclusion**

367 VTE is common in solid organ transplant recipients. The decision to choose DOAC over warfarin in  
368 this subset of patients is largely limited by the perceived risk of DDIs leading to bleeding or thrombotic  
369 concerns provoked by CNI maintenance immunosuppression therapy. DOACs have much less dose-  
370 response variability than warfarin, and accordingly do not require therapeutic monitoring, dose titration,  
371 or frequent dosage adjustments. This is an attractive option for transplant recipients requiring  
372 anticoagulation considering a large majority of individuals require lifelong chronic medications for  
373 immunosuppression and other comorbidities. Unfortunately, DOACs may be underutilized based on the  
374 DDI potential provoked by CNI use for maintenance immunosuppression. A visual is provided in **figure 2**  
375 which summarizes the available evidence relevant to the pharmacokinetic changes that best emulates

376 that of CsA and tacrolimus. In the absence of a dedicated DDI study between a particular DOAC and CNI,  
377 clinicians can extrapolate the information presented for an inhibitor that shares the same inhibitory  
378 pathway with caution. Rather, educating patients to monitor for signs of bleeding or thrombosis is  
379 encouraged at present.

380

## 381 **9. Expert Opinion**

382 For the transplant recipient, DOAC selection is individualized and based on factors that may  
383 attenuate higher or lower anticoagulant exposure while on a CNI. It is estimated that the 5-year risk of  
384 chronic kidney disease after non-renal transplant ranges between 7 to 21%.[70] Indeed renal function  
385 may decline overtime as a result of CNI exposure, age, and pre-existing comorbidities. Since a considerable  
386 fraction of DOACs are cleared by the kidneys, renal function is an important consideration when selecting  
387 an anticoagulant for the transplant recipient. Furthermore, an important consideration is the site of drug  
388 interaction. For example, interactions with dabigatran etexilate occur primarily at the absorption level  
389 where P-gp efflux in the intestines predominates. The active drug, dabigatran, is then renally cleared  
390 without further interaction with P-gp in elimination organs (e.g. biliary ducts) or drug metabolizing  
391 enzymes. In comparison, direct FXa inhibitors may have interactions occurring at the absorption and  
392 elimination phase. This may further enhance exposure and increase the probability of a bleeding event  
393 during which metabolism or excretion is inhibited (e.g. CsA). Together with declining renal function,  
394 bleeding risks may increase when both the absorption and elimination pathways are inhibited. Although  
395 one factor alone may not enhance the safety risk, presence of renal dysfunction, CNI, additional P-gp or  
396 CYP3A4 inhibitors (e.g. antifungals or antibiotics) or other covariates (e.g. extremes in body weight) may  
397 contribute to a higher likelihood of bleeding. In the case of apixaban co-administered with tacrolimus, the  
398 reduction in apixaban exposure and peak concentration does not warrant efficacy concern. However, the  
399 likelihood of any compromise to efficacy is currently unknown for individuals with  $\geq 120$  kg in body weight

400 co-medicated with apixaban and tacrolimus. Interestingly, data from a large cohort of 91,330 Taiwanese  
401 patients found no significant risk of major bleeding in combined DOAC users with concurrent use of  
402 CsA.[71] Although the population of those using CsA together with DOACs was small at 0.62%, the risk of  
403 a major bleed was observed to be five-times greater in those taking apixaban compared to propensity-  
404 score matched controls.

405           Bleeding during CsA and rivaroxaban therapy have also been reported in small observational  
406 studies.[72,73] Although the number of patients included were small, both trough rivaroxaban  
407 concentration and anti-FXa activity were within the ranges considered therapeutic at their respective  
408 doses.[74] It should be noted that with each case, the reported creatinine clearances were far below the  
409 threshold value of 80 mL/min for which rivaroxaban is contraindicated in patients receiving dual P-gp and  
410 moderate CYP3A4 inhibitors. These results reflect several important implications for clinical practice  
411 where 1) dosage adjustments should be made to reflect renal function and CNI co-administration, 2)  
412 although the use of anti-FXa activity as a correlate to plasma drug levels is appropriate for FXa inhibitors,  
413 calibration specificity of anti-FXa activity for the FXa inhibitor (i.e. rivaroxaban, apixaban, or edoxaban) is  
414 critical to make an accurate determination and 3) lastly, the choice of tacrolimus for immunosuppression  
415 may be favorable compared to CsA. In a single-center retrospective cohort study in 37 thoracic transplant  
416 patients on concomitant DOAC and CNI therapy, bleeding rates were comparable to those without DDIs  
417 during DOAC therapy.[75] Tacrolimus was used in 73% of patients with 78% of the patients on rivaroxaban.  
418 The median creatinine clearance at the initiation of DOAC therapy was 59 mL/min. DOACs were used first-  
419 line as anticoagulation therapy for VTE in this report. Lung transplant recipients received rivaroxaban as  
420 the preferred DOAC if their creatinine clearances were above 30 mL/min, whereas apixaban was selected  
421 for those with creatinine clearances less than 30 mL/min. Those with identified DDIs- including roughly a  
422 quarter of those on CsA- were found to not have any statistically significant incidences in bleeding

423 compared to those without identified DDIs. These observational studies, although limited in the sample  
424 size, may demonstrate the role of DOACs in transplant recipients requiring anticoagulation.

425         Considering that most maintenance immunosuppressive regimens now contain tacrolimus,  
426 bleeding risks with DOACs may be less of a concern from DDIs. In the case of those requiring  
427 immunosuppression using CsA, which is a P-gp, BCRP, OATP and moderate CYP3A4 inhibitor, dabigatran  
428 etexilate may be appropriate based on its predominate P-gp transport in the gastrointestinal tract. This  
429 recommendation can be complicated considering that regulatory labeling for CsA recommend against use  
430 with dabigatran etexilate.[16,17] In addition, real-world limitations such as complex physiological  
431 changes, affordability, or insurance coverage may discourage the use of one DOAC over another.

432         As thrombosis research continues, development of safer and effective anticoagulants may offer a  
433 solution to DDI concerns. As an example, darexaban, a FXa inhibitor in clinical development demonstrated  
434 no relevant interactions in the presence of strong dual P-gp and CYP3A4 inducers suggesting a low  
435 potential of clinically relevant DDIs.[74] Unfortunately, further development of the compound was  
436 discontinued. In addition, small molecules targeting factors XII and XI are in development and may provide  
437 a safer alternative to potential bleeding risks encountered with current DOACs.[75] Future research  
438 applying pharmacometric and pharmacoepidemiological methods using rich data sources like the  
439 electronic medical record would be most useful in determining the pharmacokinetic-pharmacodynamic  
440 interaction within this subgroup.

441         Taken together, clinicians should consider the complex physiological changes that affect the  
442 absorption and elimination of drugs following transplantation to fully optimize anticoagulation therapy in  
443 recipients. Monitoring for renal function is essential in order to individualize anticoagulation therapy with  
444 DOACs. Monitoring of anti-FXa levels requires a drug specific assay, drug dosed to steady state, and a rigid  
445 attention to dose and draw time. There is no standardized dose adjustment based upon anti-FXa level and  
446 for these reasons the use of monitoring is discouraged. Dosage adjustments should follow the product

447 labeling with attention to renal function. Although limited, pharmacokinetic-pharmacodynamic and  
448 observational data suggest that the use of CNIs, specifically tacrolimus, together with DOACs is safe and  
449 effective.

450 Drug doses used for primary prophylaxis of VTE are less than those used for treatment of acute  
451 thrombosis or for secondary prophylaxis for a prior thrombotic event. The magnitude of any DDI will be  
452 accordingly less. Additional bleeding events attributable to prophylactic/low dose anticoagulation are low.  
453 For these reasons, patients with solid organ transplantation should have doses of thromboprophylactics  
454 guided by the general FDA approval label for all agents. In general, if there is concern for need of an  
455 invasive procedure or short term increased bleeding risk in an inpatient setting, the use of an injectable  
456 agent such as enoxaparin or unfractionated heparin is preferable to a DOAC without a readily available  
457 reversible agent.

458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470

471 **References**

472 **\* of Interest**

473 **\*\* of considerable interest**

- 474 1. Rana A, Gruessner A, Agopian VG *et al.* Survival benefit of solid-organ transplant in the United  
475 States. *JAMA Surg*, 150(3), 252-259 (2015).
- 476 2. Costanzo MR, Dipchand A, Starling R *et al.* The International Society of Heart and Lung  
477 Transplantation Guidelines for the care of heart transplant recipients. *J Heart Lung Transplant*,  
478 29(8), 914-956 (2010).
- 479 3. Kidney Disease: Improving Global Outcomes Transplant Work G. KDIGO clinical practice  
480 guideline for the care of kidney transplant recipients. *Am J Transplant*, 9 Suppl 3, S1-155 (2009).
- 481 4. Lucey MR, Terrault N, Ojo L *et al.* Long-term management of the successful adult liver  
482 transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases  
483 and the American Society of Transplantation. *Liver Transpl*, 19(1), 3-26 (2013).
- 484 5. Saez-Gimenez B, Berastegui C, Loo K *et al.* Deep vein thrombosis and pulmonary embolism after  
485 solid organ transplantation: an unresolved problem. *Transplant Rev (Orlando)*, 29(2), 85-92  
486 (2015).
- 487 6. Irish A. Hypercoagulability in renal transplant recipients. Identifying patients at risk of renal  
488 allograft thrombosis and evaluating strategies for prevention. *Am J Cardiovasc Drugs*, 4(3), 139-  
489 149 (2004).
- 490 7. Vanrenterghem Y, Roels L, Lerut T *et al.* Thromboembolic complications and haemostatic  
491 changes in cyclosporin-treated cadaveric kidney allograft recipients. *Lancet*, 1(8436), 999-1002  
492 (1985).
- 493 8. Gruber SA, Chavers B, Payne WD *et al.* Allograft renal vascular thrombosis--lack of increase with  
494 cyclosporine immunosuppression. *Transplantation*, 47(3), 475-478 (1989).
- 495 9. Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. *J Thromb*  
496 *Thrombolysis*, 41(1), 3-14 (2016).
- 497 10. 2016 Annual Data Report. Scientific Registry of Transplant Recipients.  
498 [http://srtr.transplant.hrsa.gov/annual\\_reports/Default.aspx](http://srtr.transplant.hrsa.gov/annual_reports/Default.aspx). Accessed [July 6, 2018].).
- 499 11. Prograf (Tacrolimus) [Package Insert]. Astellas Pharma US, Inc., Northbrook, IL ).
- 500 12. Christians U, Jacobsen W, Benet LZ, Lampen A. Mechanisms of clinically relevant drug  
501 interactions associated with tacrolimus. *Clin Pharmacokinet*, 41(11), 813-851 (2002).
- 502 13. Huang F, Voelk C, Trampisch M, Rowland L, Schultz A, Sabo JP. Pharmacokinetic Interaction  
503 between Faldaprevir and Cyclosporine or Tacrolimus in Healthy Volunteers: A Prospective,  
504 Open-Label, Fixed-Sequence, Crossover Study. *Basic Clin Pharmacol Toxicol*, 123(1), 84-93  
505 (2018).
- 506 14. Lemahieu WP, Hermann M, Asberg A *et al.* Combined therapy with atorvastatin and calcineurin  
507 inhibitors: no interactions with tacrolimus. *Am J Transplant*, 5(9), 2236-2243 (2005).
- 508 **\*Drug interaction study demonstrating lack of clinical impact of tacrolimus on drug**  
509 **metabolizing enzymes and transporters.**
- 510 15. Hebert MF. Contributions of hepatic and intestinal metabolism and P-glycoprotein to  
511 cyclosporine and tacrolimus oral drug delivery. *Adv Drug Deliv Rev*, 27(2-3), 201-214 (1997).
- 512 16. Sandimmune (Cyclosporine, USP) [Package Insert]. Novartis Pharmaceuticals Corporation, East  
513 Hanover, NJ. (2015).
- 514 17. Neoral (Cyclosporine, USP [MODIFIED]) [Package Insert]. Novartis Pharmaceuticals Corporation,  
515 East Hanover, NJ. (2015).

- 516 18. Chou CL, Chou CY, Huang YY, Wu MS, Hsu CC, Chou YC. Prescription trends of  
517 immunosuppressive drugs in post-heart transplant recipients in Taiwan, 2000-2009.  
518 *Pharmacoepidemiol Drug Saf*, 23(12), 1312-1319 (2014).
- 519 19. Huang YY, Hsu CC, Chou CL, Loong CC, Wu MS, Chou YC. Trends in the use of maintenance  
520 immunosuppressive drugs among liver transplant recipients in Taiwan: a nationwide population-  
521 based study. *Pharmacoepidemiol Drug Saf*, 25(6), 661-667 (2016).
- 522 20. Paimela H. Persistence of gastric hypoacidity in uraemic patients after renal transplantation.  
523 *Scand J Gastroenterol*, 20(7), 873-876 (1985).
- 524 21. Sodhi SS, Guo JP, Maurer AH, O'Brien G, Srinivasan R, Parkman HP. Gastroparesis after  
525 combined heart and lung transplantation. *J Clin Gastroenterol*, 34(1), 34-39 (2002).
- 526 22. Bodet-Milin C, Querellou S, Oudoux A *et al*. Delayed gastric emptying scintigraphy in cystic  
527 fibrosis patients before and after lung transplantation. *J Heart Lung Transplant*, 25(9), 1077-  
528 1083 (2006).
- 529 23. Ozkaya O, Derici U, Buyan N *et al*. Gastric emptying time in renal transplant recipients treated  
530 with cyclosporine. *Transplant Proc*, 35(8), 2927-2930 (2003).
- 531 24. Kochhar G, Parungao JM, Hanouneh IA, Parsi MA. Biliary complications following liver  
532 transplantation. *World J Gastroenterol*, 19(19), 2841-2846 (2013).
- 533 25. Masuda S, Goto M, Kiuchi T *et al*. Enhanced expression of enterocyte P-glycoprotein depresses  
534 cyclosporine bioavailability in a recipient of living donor liver transplantation. *Liver Transpl*,  
535 9(10), 1108-1113 (2003).
- 536 26. Kushihara H, Kuzuya T, Miwa Y *et al*. Changes in ABCB1 mRNA Expression in Peripheral Blood  
537 Cells before and after Renal Transplantation. *Biol Pharm Bull*, 39(7), 1085-1090 (2016).
- 538 27. Sugawara Y, Makuuchi M, Kaneko J, Ohkubo T, Imamura H, Kawarasaki H. Correlation between  
539 optimal tacrolimus doses and the graft weight in living donor liver transplantation. *Clin*  
540 *Transplant*, 16(2), 102-106 (2002).
- 541 28. Baldwin MR, Arcasoy SM, Shah A *et al*. Hypoalbuminemia and early mortality after lung  
542 transplantation: a cohort study. *Am J Transplant*, 12(5), 1256-1267 (2012).
- 543 29. Becker BN, Becker YT, Heisey DM *et al*. The impact of hypoalbuminemia in kidney-pancreas  
544 transplant recipients. *Transplantation*, 68(1), 72-75 (1999).
- 545 30. Sang BH, Bang JY, Song JG, Hwang GS. Hypoalbuminemia Within Two Postoperative Days Is an  
546 Independent Risk Factor for Acute Kidney Injury Following Living Donor Liver Transplantation: A  
547 Propensity Score Analysis of 998 Consecutive Patients. *Crit Care Med*, 43(12), 2552-2561 (2015).
- 548 31. Haroldson JA, Kramer LE, Wolff DL, Lake KD. Elevated free fractions of valproic acid in a heart  
549 transplant patient with hypoalbuminemia. *Ann Pharmacother*, 34(2), 183-187 (2000).
- 550 32. Huang ML, Venkataramanan R, Burckart GJ, Ptachcinski RJ, Van Thiel DH, Starzl TE. Drug-binding  
551 proteins in liver transplant patients. *J Clin Pharmacol*, 28(6), 505-506 (1988).
- 552 33. Haughey DB, Kraft CJ, Matzke GR, Keane WF, Halstenson CE. Protein binding of disopyramide  
553 and elevated alpha-1-acid glycoprotein concentrations in serum obtained from dialysis patients  
554 and renal transplant recipients. *Am J Nephrol*, 5(1), 35-39 (1985).
- 555 34. Burckart GJ, Frye RF, Kelly P *et al*. Induction of CYP2E1 activity in liver transplant patients as  
556 measured by chlorzoxazone 6-hydroxylation. *Clin Pharmacol Ther*, 63(3), 296-302 (1998).
- 557 35. Navasa M, Feu F, Garcia-Pagan JC *et al*. Hemodynamic and humoral changes after liver  
558 transplantation in patients with cirrhosis. *Hepatology*, 17(3), 355-360 (1993).
- 559 36. Piscaglia F, Zironi G, Gaiani S *et al*. Systemic and splanchnic hemodynamic changes after liver  
560 transplantation for cirrhosis: a long-term prospective study. *Hepatology*, 30(1), 58-64 (1999).
- 561 37. Li M, Zhao Y, Humar A, Tevar AD, Hughes C, Venkataramanan R. Pharmacokinetics of drugs in  
562 adult living donor liver transplant patients: regulatory factors and observations based on studies  
563 in animals and humans. *Expert Opin Drug Metab Toxicol*, 12(3), 231-243 (2016).

- 564 **\*\*This review provides a comprehensive overview of the physiological changes in solid organ**  
565 **transplant recipients and its impact on drug pharmacokinetics.**
- 566 38. Shah JN, Haigh WG, Lee SP *et al.* Biliary casts after orthotopic liver transplantation: clinical  
567 factors, treatment, biochemical analysis. *Am J Gastroenterol*, 98(8), 1861-1867 (2003).
- 568 39. Broekroelofs J, Navis GJ, Stegeman CA *et al.* Long-term renal outcome after lung transplantation  
569 is predicted by the 1-month postoperative renal function loss. *Transplantation*, 69(8), 1624-1628  
570 (2000).
- 571 40. Lindelow B, Bergh CH, Herlitz H, Waagstein F. Predictors and evolution of renal function during 9  
572 years following heart transplantation. *J Am Soc Nephrol*, 11(5), 951-957 (2000).
- 573 41. International Transporter C, Giacomini KM, Huang SM *et al.* Membrane transporters in drug  
574 development. *Nat Rev Drug Discov*, 9(3), 215-236 (2010).
- 575 42. Gertz M, Cartwright CM, Hobbs MJ *et al.* Cyclosporine inhibition of hepatic and intestinal  
576 CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of  
577 drug-drug interaction potential. *Pharm Res*, 30(3), 761-780 (2013).
- 578 **\*\*In-silico modeling of cyclosporine's potential drug-drug interaction at the level of**  
579 **absorption and elimination.**
- 580 43. Lemahieu WP, Maes BD, Verbeke K, Vanrenterghem Y. CYP3A4 and P-glycoprotein activity in  
581 healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus. *Am J*  
582 *Transplant*, 4(9), 1514-1522 (2004).
- 583 **\*\*This study highlights the differential effect between cyclosporine and tacrolimus on**  
584 **intestinal and hepatic CYP3A4 and P-glycoprotein.**
- 585 44. Lin JH, Chiba M, Baillie TA. Is the role of the small intestine in first-pass metabolism  
586 overemphasized? *Pharmacol Rev*, 51(2), 135-158 (1999).
- 587 45. Schulman S, Kearon C, Kakkar AK *et al.* Dabigatran versus warfarin in the treatment of acute  
588 venous thromboembolism. *N Engl J Med*, 361(24), 2342-2352 (2009).
- 589 46. Investigators E, Bauersachs R, Berkowitz SD *et al.* Oral rivaroxaban for symptomatic venous  
590 thromboembolism. *N Engl J Med*, 363(26), 2499-2510 (2010).
- 591 47. Hokusai VTEI, Buller HR, Decousus H *et al.* Edoxaban versus warfarin for the treatment of  
592 symptomatic venous thromboembolism. *N Engl J Med*, 369(15), 1406-1415 (2013).
- 593 48. Agnelli G, Buller HR, Cohen A *et al.* Oral apixaban for the treatment of acute venous  
594 thromboembolism. *N Engl J Med*, 369(9), 799-808 (2013).
- 595 49. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin  
596 inhibitor dabigatran etexilate. *Clin Pharmacokinet*, 47(5), 285-295 (2008).
- 597 50. Troconiz IF, Tillmann C, Liesenfeld KH, Schafer HG, Stangier J. Population pharmacokinetic  
598 analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients  
599 undergoing primary elective total hip replacement surgery. *J Clin Pharmacol*, 47(3), 371-382  
600 (2007).
- 601 51. Hodin S, Basset T, Jacqueroux E *et al.* In Vitro Comparison of the Role of P-Glycoprotein and  
602 Breast Cancer Resistance Protein on Direct Oral Anticoagulants Disposition. *Eur J Drug Metab*  
603 *Pharmacokinet*, 43(2), 183-191 (2018).
- 604 **\*\*In-vitro study demonstrating the differential drug transporter profiles of the DOACs.**
- 605 52. Hartter S, Sennewald R, Nehmiz G, Reilly P. Oral bioavailability of dabigatran etexilate  
606 (Pradaxa((R))) after co-medication with verapamil in healthy subjects. *Br J Clin Pharmacol*, 75(4),  
607 1053-1062 (2013).
- 608 53. Zhao Y, Hu ZY. Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately  
609 predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate. *Br J*  
610 *Pharmacol*, 171(4), 1043-1053 (2014).

- 611 54. Kumar P, Gordon LA, Brooks KM *et al.* Differential Influence of the Antiretroviral  
612 Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and  
613 the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran. *Antimicrob Agents*  
614 *Chemother*, 61(11) (2017).  
615 **\*\*Drug interaction study demonstrating the time-dependent inhibition of P-glycoprotein of**  
616 **perpetrator drugs on the PK of dabigatran in healthy volunteers.**
- 617 55. Pradaxa (Dabigatran etexilate mesylate) [Package Insert]. Boehringer Ingelheim  
618 Pharmaceuticals, Inc., Ridgefield, CT. (2018).
- 619 56. Xarelto (Rivaroxaban) [Package Insert]. Janssen Pharmaceuticals, Inc., Titusville, NJ.).
- 620 57. U.S. Food and Drug Administration. Xarelto (rivaroxaban) Clinical Pharmacology  
621 Biopharmaceutics Review. Available at:  
622 [https://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2011/022406Orig1s000ClinPharmR.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022406Orig1s000ClinPharmR.pdf).  
623 Accessed July 9, 2018. .).
- 624 58. Mueck W, Kubitzka D, Becka M. Co-administration of rivaroxaban with drugs that share its  
625 elimination pathways: pharmacokinetic effects in healthy subjects. *Br J Clin Pharmacol*, 76(3),  
626 455-466 (2013).  
627 **\*\*Drug interaction study between rivaroxaban and perpetrator drugs that share the**  
628 **interaction profile of calcineurin inhibitors in healthy volunteers.**
- 629 59. Grillo JA, Zhao P, Bullock J *et al.* Utility of a physiologically-based pharmacokinetic (PBPK)  
630 modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario  
631 for rivaroxaban during the drug review process: implications for clinical practice. *Biopharm Drug*  
632 *Dispos*, 33(2), 99-110 (2012).
- 633 60. Savaysa (Edoxaban) [Package Insert]. Daiichi Sankyo, Inc., Basking Ridge, NJ.).
- 634 61. U.S. Food and Drug Administration. Savaysa (edoxaban) Clinical Pharmacology Biopharmaceutics  
635 Review. Available at  
636 [https://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2015/206316Orig1Orig2s000ClinPharmR](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206316Orig1Orig2s000ClinPharmR.pdf)  
637 [.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206316Orig1Orig2s000ClinPharmR.pdf). Accessed July 9, 2018.).
- 638 62. Parasrampur DA, Mendell J, Shi M, Matsushima N, Zahir H, Truitt K. Edoxaban drug-drug  
639 interactions with ketoconazole, erythromycin, and cyclosporine. *Br J Clin Pharmacol*, 82(6),  
640 1591-1600 (2016).  
641 **\*\*Drug interaction study between cyclosporine on edoxaban PK in healthy volunteers.**
- 642 63. Nyberg J, Karlsson KE, Jonsson S *et al.* Edoxaban Exposure-Response Analysis and Clinical Utility  
643 Index Assessment in Patients With Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism.  
644 *CPT Pharmacometrics Syst Pharmacol*, 5(4), 222-232 (2016).
- 645 64. Eliquis (Apixaban) [Package Insert]. Bristol-Myers Squibb Company, Princeton, NJ.).
- 646 65. Byon W, Nepal S, Schuster AE, Shenker A, Frost CE. Regional Gastrointestinal Absorption of  
647 Apixaban in Healthy Subjects. *J Clin Pharmacol*, 58(7), 965-971 (2018).  
648 **\*Healthy volunteer study of apixaban absorption PK in various regions of the gastrointestinal**  
649 **tract.**
- 650 66. Zhang D, He K, Herbst JJ *et al.* Characterization of efflux transporters involved in distribution and  
651 disposition of apixaban. *Drug Metab Dispos*, 41(4), 827-835 (2013).
- 652 67. Byon W, Sweeney K, Frost C, Boyd RA. Population Pharmacokinetics, Pharmacodynamics, and  
653 Exploratory Exposure-Response Analyses of Apixaban in Subjects Treated for Venous  
654 Thromboembolism. *CPT Pharmacometrics Syst Pharmacol*, 6(5), 340-349 (2017).
- 655 68. Bashir B, Stickle DF, Chervoneva I, Kraft WK. Drug-Drug Interaction Study of Apixaban with  
656 Cyclosporine and Tacrolimus in Healthy Volunteers. *Clin Transl Sci*, (2018).  
657 **\*\*Drug interaction study between cyclosporine and tacrolimus on apixaban PK in healthy**  
658 **volunteers.**

- 659 69. U.S. Food and Drug Administration. Eliquis (apixaban) Clinical Pharmacology Biopharmaceutics  
660 Review. Available at:  
661 [https://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2012/202155Orig1s000ClinPharmR.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202155Orig1s000ClinPharmR.pdf).  
662 Accessed July 9, 2018.).
- 663 70. Ojo AO, Held PJ, Port FK *et al*. Chronic renal failure after transplantation of a nonrenal organ. *N*  
664 *Engl J Med*, 349(10), 931-940 (2003).  
665 **\*\*Incidence of chronic renal failure following a non-renal organ transplant. The incidence of**  
666 **renal failure has important implications on the dosing and renal elimination of DOACs.**
- 667 71. Chang SH, Chou IJ, Yeh YH *et al*. Association Between Use of Non-Vitamin K Oral Anticoagulants  
668 With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial  
669 Fibrillation. *JAMA*, 318(13), 1250-1259 (2017).  
670 **\*\*First large-scale pharmacoepidemiological study of drug interactions between DOACs co-**  
671 **administered with calcineurin inhibitors.**
- 672 72. Wannhoff A, Weiss KH, Schemmer P, Stremmel W, Gotthardt DN. Increased levels of  
673 rivaroxaban in patients after liver transplantation treated with cyclosporine A. *Transplantation*,  
674 98(2), e12-13 (2014).  
675 **\*Observational study describing elevated rivaroxaban exposures in patients treated with**  
676 **cyclosporine.**
- 677 73. Ambrosi P, Kreitmann B, Cohen W, Habib G, Morange P. Anticoagulation with a new oral  
678 anticoagulant in heart transplant recipients. *Int J Cardiol*, 168(4), 4452-4453 (2013).
- 679 74. Samuelson BT, Cuker A, Siegal DM, Crowther M, Garcia DA. Laboratory Assessment of the  
680 Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review. *Chest*, 151(1), 127-  
681 138 (2017).
- 682 75. Lichvar AB, Moore CA, Ensor CR, McDyer JF, Teuteberg JJ, Shullo MA. Evaluation of Direct Oral  
683 Anticoagulation Therapy in Heart and Lung Transplant Recipients. *Prog Transplant*, 26(3), 263-  
684 269 (2016).
- 685

686 **Table 1.** Summary changes to DOAC pharmacokinetics measured as changes in peak concentrations (Cmax) and exposure (AUC).

Drug	In-vitro Transporter Affinity	Perpetrator	Victim / Perpetrator Regimen Studied	Effect of P-gp and/or CYP3A4 Inhibition	Comments	Reference
<b>Dabigatran</b>	Predominantly P-gp dependent transport	Verapamil	Single-dosed DE 150 mg 2 hours before + verapamil IR 120 mg BID	Cmax: ↑18% AUC: ↑12%	Do not use together with P-gp inhibitor if creatinine clearance is < 50 mL/min. Labeling for both cyclosporine formulations suggest avoiding co-administration with dabigatran.	[16, 17, 51, 52, 53]
		Ritonavir	Single-dosed DE 150 mg 2 hours before + ritonavir 100 mg daily	Cmax: ↓ 27% AUC: ↓ 29%		
		Ritonavir	Single-dosed DE 150 mg + ritonavir 100 mg daily	Cmax: ↑13% AUC: ↑15%		
<b>Rivaroxaban</b>	Equivalent P-gp & BCRP transport	Fluconazole	Single-dose rivaroxaban 20 mg+ fluconazole 400 mg daily for 5 days	Cmax: ↑28% AUC: ↑42%	Do not use together with P-gp and strong CYP3A4 inhibitor if creatinine clearance < 80 mL/min. No dedicated CsA or Tacrolimus DDI conducted. Fluconazole is a BCRP inhibitor. Erythromycin is a P-gp and moderate CYP3A4 inhibitor.	[51, 58]
		Erythromycin	Single-dose rivaroxaban 10 mg +erythromycin 500 mg TID for 4 days	Cmax: ↑38% AUC: ↑34%		

<b>Edoxaban</b>	Equivalent P-gp & BCRP transport	Cyclosporine	Single-dose edoxaban 60 mg + single-dose CsA 500 mg	C <sub>max</sub> : ↑ 74% AUC: ↑ 73%	Recommended dose of 30 mg once-daily. Patients on CsA were excluded from pivotal VTE trial. CsA is an inhibitor of OATP1B1 uptake for M4 metabolite.	[51, 62]
<b>M4 (active metabolite)</b>	Unknown	Cyclosporine		C <sub>max</sub> : ↑ 8.7 fold AUC: ↑ 6.9 fold		
<b>Apixaban</b>	Preferential BCRP-dependent transport	Cyclosporine	Single-dose apixaban 10 mg + CsA 100 mg daily for 3 days	C <sub>max</sub> : ↑ 43% AUC: ↑ 20%	No clinically meaningful impact on efficacy or safety with elevated exposure together with CsA; reduced exposure together with tacrolimus.	[51, 68]
		Tacrolimus	Single-dose apixaban 10 mg + tacrolimus 5 mg daily for 3 days	C <sub>max</sub> : ↓ 13% AUC: ↓ 22%		

687 AUC: Area under the plasma-concentration time curve extrapolated to infinity, BCRP: Breast Cancer Resistance Protein, BID: Twice-daily, C<sub>max</sub>: Peak  
688 plasma concentration, CsA: Cyclosporine, DDI: Drug-drug interaction, DE: Dabigatran etexilate, IR: Immediate-release, OATP: Organic anion  
689 transporting polypeptide1B1, P-gp: Permeability glycoprotein, TID: Three times-daily

690  
691  
692  
693  
694  
695  
696  
697  
698  
699

700 **Figure 1.** Physiological changes following solid organ transplantation that impact the pharmacokinetics (absorption, distribution, metabolism, and  
701 excretion) of drugs.

702

703

704

705

706

707

708

709

710

711

712

713


714

715

716

717

718



719 The illustration is a derivative of “Arterial circulation”, “Arrow”, “Capsule”, and “Complete digestive apparatus” by Servier Medical Art  
720 (<https://smart.servier.com/>) under the Creative Commons License (CC BY 3.0).

721 **Figure 2:** Effect of cyclosporine, tacrolimus, or similar perpetrator drugs on the pharmacokinetics of DOACs.

722

723

724

725

726

727

728

729

730

731

732

733


734

735

736

737

738



739 Results from dedicated drug-drug interaction studies in healthy-volunteers for dabigatran, rivaroxaban, edoxaban (and M4 metabolite), and  
 740 apixaban. Reference values for the individual direct oral anticoagulant are for the AUC and C<sub>max</sub> parameters in the absence of the co-administered  
 741 drugs. C<sub>max</sub>, peak concentrations. AUC, area under the plasma concentration-time curve from time zero extrapolated to infinity. CI, confidence  
 742 interval.